ABBVIE INC. (ABBV)
AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohns Disease
AbbVie Submits Regulatory Application to FDA for SKYRIZI® (risankizumab-rzaa) Subcutaneous Induction for Adults with Moderately to Severely Active Crohns Disease
📈 **POSITIVE** • Medium confidence analysis (71%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business